Key Issues in the Statistical Interpretation of Randomized Clinical Trials

Area of Science:

• Cardiovascular Medicine
• Biostatistics
• Clinical Trial Design

Background:

• Randomized clinical trials (RCTs) traditionally rely on P values and null hypothesis significance testing.
• A P value threshold of < 0.05 is often rigidly applied, leading to potential misinterpretations in clinical practice.
• Limitations of P values are well-documented in statistics but less emphasized in clinical literature.

Purpose of the Study:

• To critically examine the statistical limitations and interpretative pitfalls in analyzing RCTs.
• To illustrate how common statistical practices can undermine the reliability of even landmark cardiovascular trials.
• To enhance clinicians' ability to accurately interpret research findings and statistical evidence.

Main Methods:

• Review of contemporary cardiovascular literature with examples from surgical, interventional, heart failure, and pharmacotherapy trials.
• Discussion of statistical concepts including effect size, statistical power, researcher degrees of freedom, and strength of evidence.
• Analysis of interpretative challenges in positive, negative, and noninferiority trial assessments.

Main Results:

• Even prominent RCTs can suffer from statistical issues that compromise their conclusions.
• Overestimation of effect size and issues with statistical power are common.
• Misinterpretation of noninferiority trials and the impact of researcher degrees of freedom can lead to unreliable results.

Conclusions:

• Clinicians must critically evaluate statistical methodologies and interpretations in RCTs.
• A deeper understanding of statistical nuances beyond P values is crucial for evidence-based practice.
• Accurate interpretation of statistical evidence, considering effect size and study robustness, is essential for reliable clinical decision-making.